Autoimmune liver disease. Current standards, future directions.
The diagnosis and management of autoimmune hepatitis continues to evolve as new diagnostic tests and new therapies are added to the armamentarium. Also encouraging are the advances in the understanding of the human immune system and its involvement in the origin and course of auto immune diseases in general and in the variants of autoimmune liver disease. Promising changes are expected in the next few years as new medications become available to the practicing hepatologist. New immune tests may allow therapies to be customized to patients, and antiviral therapies may also eventually be used in the management of this autoimmune liver diseases.
Gish
R G
RG
Departments of Medicine and Transplantation, California Pacific Medical Center, San Francisco, California, USA. gishr@sutterhealth.org
Mason
A
A
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000145:classification / Q000175:diagnosis / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use; D002756:Cholagogues and Choleretics / Q000627:therapeutic use; D015209:Cholangitis, Sclerosing / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D019693:Hepatitis, Autoimmune / Q000175:diagnosis / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008105:Liver Cirrhosis, Biliary / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D008107:Liver Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000276:immunology; D016031:Liver Transplantation; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D014580:Ursodeoxycholic Acid / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D002756:Cholagogues and Choleretics; D007166:Immunosuppressive Agents; D014580:Ursodeoxycholic Acid; D001379:Azathioprine; D011241:Prednisone